QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cantor-fitzgerald-reiterates-neutral-on-alnylam-pharmaceuticals-maintains-220-price-target

Cantor Fitzgerald analyst Olivia Brayer reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Neutral and maintains $220 p...

 rbc-capital-reiterates-outperform-on-alnylam-pharmaceuticals-maintains-300-price-target

RBC Capital analyst Luca Issi reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and maintains $300 price ta...

 b-of-a-securities-maintains-buy-on-alnylam-pharmaceuticals-raises-price-target-to-307

B of A Securities analyst Tazeen Ahmad maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price targe...

 hc-wainwright--co-reiterates-buy-on-alnylam-pharmaceuticals-maintains-400-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintains $...

 alnylam-pharmaceuticals-stock-falls-after-detailed-vutrisiran-data-for-a-condition-with-stiff-heart-muscles

Alnylam Pharmaceuticals shares drop as detailed results from the HELIOS-B Phase 3 study of vutrisiran for ATTR-CM reveal mixed ...

 alnylam-says-typo-in-presentation-misstated-heart-drug-benefit

- Company Call

 jp-morgan-maintains-neutral-on-alnylam-pharmaceuticals-raises-price-target-to-280

JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Neutral and raises the price target fro...

 hc-wainwright--co-reiterates-buy-on-alnylam-pharmaceuticals-maintains-400-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintains $...

 goldman-sachs-upgrades-alnylam-pharmaceuticals-to-buy-raises-price-target-to-370

Goldman Sachs analyst Salveen Richter upgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Neutral to Buy and raises the pric...

 alnylam-pharmaceuticals-to-present-helios-b-phase-3-study-results-of-vutrisiran-at-esc-congress-2024-announces-topline-results-demonstrating-significant-reduction-in-mortality-and-cardiovascular-events

Company To Host Conference Call And Investor Webcast On August 30, 2024

 doordash-and-exact-sciences-are-among-top-10-large-cap-gainers-last-week-july-28-aug-3-are-the-others-in-your-portfolio

Top 10 stocks with highest gains last week, including Exact Sciences, Alnylam Pharmaceuticals, Resmed, Coca-Cola Consolidated, ...

 rbc-capital-maintains-outperform-on-alnylam-pharmaceuticals-raises-price-target-to-300

RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and raises the price target ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION